Glenmark Pharmaceuticals Financial Results
- Market cap
- ₹64,514 crore
- P/E
- 35.9
- P/B
- 6.14
- ROE
- 14.1%
- Dividend yield
- 0.11%
For the year ended Mar 2019, Glenmark Pharmaceuticals reported revenue of ₹9,865 crore and net profit of ₹925 crore, against ₹10,641 crore and ₹776 crore a year earlier.
Glenmark Pharmaceuticals annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9,865 | 10,641 | 10,944 | 12,305 | 11,432 | 11,635 | 13,146 | 16,711 | 17,584 |
| Expenses | 8,280 | 8,943 | 8,860 | 9,985 | 9,784 | 10,422 | 10,791 | 12,115 | 12,787 |
| Operating profit | 1,586 | 1,698 | 2,084 | 2,320 | 1,648 | 1,213 | 2,354 | 4,597 | 4,797 |
| Operating margin % | 16% | 16% | 19% | 19% | 14% | 10% | 18% | 28% | 27% |
| Other income | 375 | 192 | 95 | -94 | -490 | -79 | -262 | -1,830 | -1,443 |
| Interest | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 204 |
| Depreciation | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 617 |
| Profit before tax | 1,301 | 1,096 | 1,382 | 1,441 | 240 | 36 | 1,399 | 1,985 | 2,533 |
| Tax % | 29% | 29% | 30% | 31% | 137% | 5,117% | 25% | 31% | 29% |
| Net profit | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,798 |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 63.71 |
| Dividend payout % | — | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Glenmark Pharmaceuticals financial results — frequently asked questions
What is Glenmark Pharmaceuticals' annual revenue and net profit?
For the financial year ended Mar 2019, Glenmark Pharmaceuticals' revenue was ₹9,865 crore and net profit ₹925 crore; net profit rose 19.20% from ₹776 crore in Mar 2020.
How fast has Glenmark Pharmaceuticals grown over three years?
From Mar 2022 to Mar 2019, Glenmark Pharmaceuticals' revenue grew at a compound annual rate of -7.1% and net profit at -2.4%. Past growth does not indicate future results.
What is the EPS of Glenmark Pharmaceuticals?
Annual EPS for Mar 2019 was ₹0.00.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Glenmark Pharmaceuticals With ATS
Track GLENMARK live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.